Want to join the conversation?
On completion of the Stemcentrx acquisition, $ABBV intends to execute an accelerated share repurchase program of up to $4Bil of the company's common stock. Company expects the deal to reduce EPS by about $0.20 in 2016, with addition to EPS beginning in 2020. $ABBV is updating its 2016 adjusted diluted EPS outlook to $4.62-4.82.
$NFLX a monster move, going up. Expect making some money on Monday.
$AMD down more than 6% even after posting above consensus third quarter results.
$MCD stock rose more than 2% after it posted better than expected 3Q16 results, driven by global same-store sales growth. Meanwhile, earnings and revenue were lower than last year, hurt by refranchising efforts.